Currus Biologics

Based in Australia and founded in 2021, Currus Biologics operates as a biotechnology company developing CAR-T cell therapies utilizing its proprietary BEAT technology to treat solid tumor cancers. In June 2021, Currus Biologics raised AUD 10 million in series A funding led by Brandon Capital Partners, with participation from Uniseed. As of December 2022, the company is led by Sam Cobb, founding Chief Executive Officer. Currus Biologics combines its proprietary Bispecific Engagers of Antigen Presenting Cells and T cells (BEAT) technology with CAR-T therapy to engage with professional antigen-presenting cells (APCs) in the lymph nodes, away from the suppressive tumor microenvironment.

The BEAT is a bi-specific antibody, which recognizes and simultaneously binds to the CAR-T cells as well as professional antigen-presenting cells, enabling their direct interaction. This in turn appropriately activates the T cells, enabling them to then seek out and destroy solid tumor cells. The company intends to use series A funding to improve the CAR-T cell therapies against solid tumours such as breast, ovarian and pancreatic cancers.